why choose us

First received: July 16, 2022

Clinical Trial: Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Study Status: Completed

Recruit Status: RECRUITING

Condition: Insulin Receptor Mutation

Study Type: INTERVENTIONAL


Official Title: Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

Brief Summary: Background:Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue.Many people with LDs become severely insulin resistant.Some people are insulin resistant because of a variant in the insulin receptor gene.Insulin resistance causes many health problems.Objective:To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.Eligibility:Adults aged 18 to 65 years with either a known variant in the insulin…

Read more